rs142704083
Variant summary
Our verdict is Benign. The variant received -8 ACMG points: 1P and 9B. PP2BP4_StrongBP6BS1
The NM_000388.4(CASR):c.3091G>A(p.Gly1031Ser) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000105 in 1,614,220 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 17/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G1031D) has been classified as Uncertain significance.
Frequency
Consequence
NM_000388.4 missense
Scores
Clinical Significance
Conservation
Publications
- autosomal dominant hypocalcemia 1Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Illumina, ClinGen, Labcorp Genetics (formerly Invitae)
- familial hypocalciuric hypercalcemia 1Inheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), ClinGen, Illumina, Orphanet, Genomics England PanelApp
- neonatal severe primary hyperparathyroidismInheritance: AR, AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, ClinGen, Labcorp Genetics (formerly Invitae)
- autosomal dominant hypocalcemiaInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- epilepsy, idiopathic generalized, susceptibility to, 8Inheritance: AD Classification: LIMITED Submitted by: Labcorp Genetics (formerly Invitae)
- epilepsyInheritance: AD Classification: NO_KNOWN Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Benign. The variant received -8 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CASR | ENST00000639785.2 | c.3091G>A | p.Gly1031Ser | missense_variant | Exon 7 of 7 | 1 | NM_000388.4 | ENSP00000491584.2 | ||
CASR | ENST00000498619.4 | c.3121G>A | p.Gly1041Ser | missense_variant | Exon 7 of 7 | 1 | ENSP00000420194.1 | |||
CASR | ENST00000638421.1 | c.3091G>A | p.Gly1031Ser | missense_variant | Exon 7 of 7 | 5 | ENSP00000492190.1 | |||
CASR | ENST00000490131.7 | c.2860G>A | p.Gly954Ser | missense_variant | Exon 5 of 5 | 5 | ENSP00000418685.2 |
Frequencies
GnomAD3 genomes AF: 0.000572 AC: 87AN: 152208Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.000179 AC: 45AN: 251382 AF XY: 0.000110 show subpopulations
GnomAD4 exome AF: 0.0000561 AC: 82AN: 1461894Hom.: 1 Cov.: 37 AF XY: 0.0000454 AC XY: 33AN XY: 727248 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.000571 AC: 87AN: 152326Hom.: 0 Cov.: 32 AF XY: 0.000550 AC XY: 41AN XY: 74496 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
not specified Uncertain:1Benign:2
Variant summary: CASR c.3091G>A (p.Gly1031Ser) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function (ACMG BP4). The variant allele was found at a frequency of 0.00022 in 277196 control chromosomes, predominantly at a frequency of 0.0022 within the African subpopulation in the gnomAD database, including 1 homozygote. The observed variant frequency within African control individuals in the gnomAD database is approximately 176 fold of the estimated maximal expected allele frequency for a pathogenic variant in CASR causing Familial Hypocalciuric Hypercalcemia phenotype (1.3e-05), strongly suggesting that the variant is a benign polymorphism found primarily in populations of African origin (ACMG BS1). To our knowledge, no occurrence of c.3091G>A in individuals affected with Familial Hypocalciuric Hypercalcemia and no experimental evidence demonstrating its impact on protein function have been reported. This variant was previously classified as a VUS-possibly pathogenic variant that was converted during ClinVar submission to likely pathogenic in 2011. Two clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. One laboratory classified the variant as likely benign, and one laboratory classified the variant as uncertain significance. No new evidence supporting a pathogenic outcome has emerged over a span of eight years (2011-2019). Based on the evidence outlined above, the variant was classified as likely benign. -
- -
- -
Nephrolithiasis/nephrocalcinosis Benign:1
This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Familial hypocalciuric hypercalcemia 1 Benign:1
- -
Autosomal dominant hypocalcemia 1;C1809471:Familial hypocalciuric hypercalcemia Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at